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Abstract
Background—It is unknown to what extent the non-HIV population utilises laboratories 
supported by the President's Emergency Plan for AIDS Relief (PEPFAR).
Objectives—We aimed to describe the number and proportion of laboratory tests performed in 
2009 and 2011 for patients referred from HIV and non-HIV services (NHSs) in a convenience 
sample collected from 127 laboratories supported by PEPFAR in Tanzania. We then compared 
changes in the proportions of tests performed for patients referred from NHSs in 2009 vs 2011.
Methods—Haematology, chemistry, tuberculosis and syphilis test data were collected from 
available laboratory registers. Referral sources, including HIV services, NHSs, or lack of a 
documented referral source, were recorded. A generalised linear mixed model reported the odds 
that a test was from a NHS.
Results—A total of 94 132 tests from 94 laboratories in 2009 and 157 343 tests from 101 
laboratories in 2011 were recorded. Half of all tests lacked a documented referral source. Tests 
from NHSs constituted 42% (66 084) of all tests in 2011, compared with 31% (29 181) in 2009. A 
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test in 2011 was twice as likely to have been referred from a NHS as in 2009 (adjusted odds ratio: 
2.0 [95% confidence interval: 2.0–2.1]).
Conclusion—Between 2009 and 2011, the number and proportion of tests from NHSs increased 
across all types of test. This finding may reflect increased documentation of NHS referrals or that 
the laboratory scale-up originally intended to service the HIV-positive population in Tanzania may 
be associated with a ‘spillover effect’ amongst the general population.
Introduction
Investment in strengthening laboratory systems in resource-poor countries is critical to meet 
health needs across major diseases such as HIV/AIDS and to meet the United Nations 
Millennium Development Goals.1 In the past decade, the US government has invested over 
$15 billion in HIV prevention, care and treatment in low- and middle-income countries via 
the President's Emergency Plan for AIDS Relief (PEPFAR).2 This support has included a 
wide range of activities aimed at strengthening health services, including laboratories, to 
provide services for persons living with HIV (PLWH). Although the positive impact of these 
targeted health services on PLWH is undeniable, the effect of HIV service scale-up on 
broader health systems, including services for patients without HIV, has been 
debated.3,4,5,6,7
Since 2006, PEPFAR has provided over $440 million to strengthen laboratory systems 
through improved infrastructure and equipment, human resources and training, quality 
improvement, and technical assistance.8 This investment has expanded laboratory services 
such as diagnostic and monitoring tests for PLWH. Because these laboratory investments 
support health facilities serving a broad population of patients, not just PLWH, it is plausible 
that they may have affected, or in the future could affect, the coverage and quality of 
laboratory services used by the general population – that is, individuals with no known HIV 
infection.9 To our knowledge, no studies have explored this question yet.
In an effort to describe PEPFAR's investment in laboratory services for the general 
population, we analysed routinely collected programmatic data from selected public 
laboratories in Tanzania. Specifically, we selected a convenience sample of PEPFAR-
supported laboratories in Tanzania, which are supported through ICAP at Columbia 
University.10 In these laboratories, the only information distinguishing the HIV status of the 
patient from whom the test was collected was the test's referral source; that is, an HIV 
service or a non-HIV service (NHS) (e.g. general medical or outpatient services). Although 
referral source is not a definitive diagnosis of HIV status, it was the only routinely recorded 
information available as a proxy for HIV status. Our primary objective was to describe the 
number and proportion of selected core laboratory tests performed for patients referred from 
the respective services in 2011. A secondary objective was to compare changes in 
proportions of tests performed for patients referred from NHSs in 2009 and 2011.
McNairy et al. Page 2













Research method and design
Ethical considerations
This study was approved by the Columbia University Medical Center Institutional Review 
Board, the US Centers for Disease Control and Prevention, the Tanzania National Institute 
for Medical Research and the Zanzibar Medical Research and Ethics Committee.
Study population
We conducted a retrospective cross-sectional analysis of laboratory tests from 2009 and 
2011 in a convenience sample of PEPFAR-supported public laboratories in Tanzania. All 
laboratories received PEPFAR support from ICAP at Columbia University. Laboratories that 
were included were all categorised as public sector, offered integrated laboratory services 
for all laboratory samples (i.e. using the same staff and equipment for HIV and non-HIV 
patients), performed at least haematology testing over the study period, and had available 
laboratory register data on preliminary assessment. Data abstracted from laboratory testing 
registers did not include patient-identifying information.
Definitions of laboratory tests and outcomes
A laboratory test was defined as the presence of a documented haematology, chemistry, 
tuberculosis or syphilis test result in a laboratory register located at the laboratory facility. A 
haematology test result was defined as any automated or manual test for haemoglobin or a 
complete blood count (e.g. Celldyne 1800, Coulter). A chemistry test result was defined as 
creatinine or liver function tests (alanine aminotransferase, aspartate aminotransferase or 
alkaline phosphatase) or other blood chemistry panel results from an automated machine 
(e.g. Humastar 80, Hitachi, Reflotron). A tuberculosis test included a microscopy smear or 
culture. A syphilis test result was defined as a test from a venereal disease research 
laboratory or a rapid plasma reagin or antibody test. On-site registers were used to classify 
samples as from HIV services, a NHS, or an unknown referral source (i.e. did not have a 
documented referral source).
The primary outcome of this study was the proportion of laboratory tests with documented 
NHS referral sources amongst all tests with a referral source (either HIV or NHS referral). 
Other outcomes included the proportion of laboratory tests performed with documented 
NHS referral sources amongst all tests, including tests with and without referral sources.
Site-level variables
Programmatic information was used to provide contextual information about included 
laboratories. Routinely collected quarterly monitoring and evaluation data from the co-
located HIV care and treatment facilities were used to quantify the number of years each 
facility had provided HIV care services and the number of HIV-positive patients enrolled in 
the HIV care service. Information from facility-based surveys completed in 2009 and 2011 
at laboratories included the location type (urban vs rural) and type of facility (primary, 
secondary or tertiary); the 2011 survey also described the number of trained laboratory 
personnel working in each laboratory.
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Between March and July of 2013, study staff extracted de-identified laboratory data from 
on-site hard-copy registers at included laboratories. Study staff met briefly with laboratory 
personnel to assess the availability of laboratory registers for each of the aforementioned 
tests. Study staff reviewed the available laboratory registers to tally the number of each type 
of test conducted per month. Totals were aggregated by the type of referral source. If an 
HIV clinic was indicated as a referral source, the test was categorised as coming from an 
HIV service. If another clinic or unit within the facility was documented as the source in the 
register, the test was categorised as coming from a NHS. If no source was documented for 
the patient, the test was categorised as coming from an unknown referral source.
Statistical analysis
Proportions of tests conducted amongst all the laboratories were calculated for specimens 
referred from HIV services, NHSs and those with an unknown referral source. Proportions 
were calculated by year and by test type. A generalised linear mixed model was constructed 
to predict the odds that a laboratory test was referred from a NHS, taking into account 
intrafacility correlations. We used a generalised linear mixed model without confounders to 
account for intrafacility correlation, and an adjusted generalised linear mixed model that 
controlled for key facility-level variables including year, facility location and total volume 
of tests performed at each facility as fixed effects, with the laboratory treated as the random 
effect. Key contextual variables hypothesised to affect the proportion of tests from an HIV 
service compared with from a NHS, such as location (rural vs. urban), region, facility type 
and service size (e.g. number of patients enrolled in HIV care) were assessed individually to 
determine an unadjusted odds ratio. Candidate confounders (P < 0.25 when unadjusted) 
were entered and examined in generalised linear mixed models, but only the significant 
variables (P < 0.05) were kept in the final models for the purposes of calculating the 
adjusted odds ratios. All analyses were conducted using SAS version 9.3 (SAS Institute, 
Cary, North Carolina, United States).
Results
Amongst the 127 PEPFAR-supported laboratories in Tanzania during the study period, 94 
laboratories had testing data available from registers in 2009 and 101 laboratories had 
testing data available from registers in 2011 (Figure 1). A total of 93 laboratories had testing 
data for both 2009 and 2011. When the analysis was restricted to laboratories whose 
registers included tests with a referral source, a total of 51 in 2009 and 61 laboratories in 
2011 remained in the sample.
Characteristics of laboratory facilities
The majority of laboratories were located in an urban area (Table 1). In 2009, there were 59 
(63%) primary level laboratories, whereas in 2011 there were 66 (65%). In 2009, 70% of 
laboratories had been providing HIV care for up to one year, compared with 2% in 2011; in 
2011, 67% had been providing HIV care for two to three years and 31% had been providing 
HIV care for at least four years. The median number of PLWH enrolled in care at PEPFAR-
supported HIV facilities increased from 139 in 2009 to 269 in 2011. Data were not available 
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on the median number of laboratory technicians in 2009, but 40% of laboratories had one 
technician in 2011, 32% of laboratories had two or three technicians in that year and 29% 
had at least four technicians. The median number of laboratory tests documented in 
available on-site registers was 415 tests (interquartile range [IQR]: 108–1211) in 2009 and 
652 tests (IQR: 217–2034) in 2011. The number and proportion of laboratories conducting 
more than 1500 tests per year increased from 18 (19%) in 2009 to 28 (28%) in 2011.
The completeness of available data at laboratories varied according to the type of test and 
over time. The proportion of laboratories providing any data on haematology tests increased 
from 64% (60/94) in 2009 to 92% (93/101) in 2011 (P < 0.001) (Table 1). The proportion of 
laboratories providing any data on other tests increased measurably but not significantly 
from 2009 to 2011: 13% (12/94) vs. 23% (23/101) for chemistry tests (P = 0.07), 85% 
(80/94) vs. 88% (89/101) for tuberculosis tests (P = 0.53), and 32% (30/94) vs. 46% 
(46/101) for syphilis tests (P = 0.05). Of the 94 laboratories providing data in 2009, 61% 
(57/94) provided data for 12 months of the year compared with 75% (75/101) in 2011 (data 
not shown in table 1).
Characteristics of laboratory tests
The total number of tests recorded increased from 94 132 in 94 laboratories in 2009 to 157 
343 in 101 laboratories in 2011 (Table 2). The proportion of all tests performed for patients 
referred from a NHS increased from 31% (29 181) in 2009 to 42% (66 084) in 2011 (Figure 
2). In both years, less than one-fifth of all tests were documented as being referred from HIV 
services: 14% (13 178) in 2009 and 11% (17 308) in 2011. Approximately half of all tests 
lacked a documented referral source: 56% (52 714) in 2009 and 47% (73 951) in 2011.
Haematology tests constituted the majority of all tests documented in the two study periods, 
accounting for 58% (54 499) of all tests in 2009 and 67% (104 693) of tests in 2011 (Table 
2; Figure 2). The proportion of haematology tests performed for patients referred from a 
NHS increased from 34% in 2009 to 45% in 2011. Less than 10% of haematology tests in 
either year were performed for patients with a documented referral from HIV services (8% 
in 2009 and 9% in 2011). In contrast, chemistry tests represented a much smaller proportion 
of the total number of tests: 13% (12 607) in 2009 and 11% (17 680) in 2011. However, the 
proportion of chemistry tests performed for patients referred from HIV services was much 
larger than any other test type (45% in 2009 and 40% in 2011). The vast majority of all 
tuberculosis tests in 2009 and 2011 had an unknown referral source: 78% (13 648) in 2009 
and 64% (13 792) in 2011. Syphilis testing increased from 9528 tests in 2009 to 13 420 tests 
in 2011. The proportion of syphilis tests recorded for patients referred from HIV services 
decreased from 24% (2287) in 2009 to 2% (268) in 2011 and was accompanied by a large 
increase in the proportion of tests performed for patients with an unknown referral source: 
from 44% (4192) in 2009 to 62% (8320) in 2011.
When analyses were restricted only to tests with a documented referral source, the sample of 
laboratories decreased from 94 to 51 in 2009 and from 101 to 61 in 2011. Amongst this 
sample, the proportion of all laboratory tests performed for patients referred from NHSs 
increased from 69% (28 722) in 2009 to 76% (63 462) in 2011 (Figure 3). The proportion of 
haematology tests performed for patients referred from NHSs increased modestly from 82% 
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(18 722) in 2009 to 84% (46 936) in 2011, yet dramatically in net number. The proportion of 
chemistry tests performed for patients referred from NHSs increased from 40% (3795) in 
2009 to 52% (7461) in 2011, and the proportion of tuberculosis diagnostic tests increased 
from 78% (3046) to 81% (6323) during this same period. The proportion of syphilis tests 
performed for patients referred from NHSs increased the most: from 58% (3107) in 2009 to 
95% (4810) in 2011.
For all laboratory tests, tests were approximately twice as likely to be referred from NHSs in 
2011 compared with 2009, based on the unadjusted odds ratio of 1.9 (95% confidence 
interval [CI]: 1.8–1.9) (Table 3). A similar odds ratio was estimated after adjusting for year, 
location and number of tests conducted (adjusted odds ratio: 2.0 [95% CI: 2.0–2.1]). When 
stratified by test type, we found that amongst all types of test, chemistry and syphilis tests 
were the most likely to have been referred from NHSs in 2011 compared with 2009 
(adjusted odds ratios: 1.9 [95% CI: 1.7–2.0] for chemistry; 13.0 [95% CI: 11.0–17.0) for 
syphilis]). Haematology tests performed in urban laboratories were more likely to be 
referred from NHSs than haematology tests from rural laboratories (adjusted odds ratio: 6.8 
[95% CI: 1.2–40.0]). Samples that came from laboratories that conducted fewer tests (< 500 
and 501–1500 per year) were more than twice as likely to be referred from NHSs compared 
with those from laboratories that conducted a larger number of tests (> 1500) per year 
(adjusted odds ratios: 2.5 [95% CI: 1.9–3.3] for < 500 tests and 2.6 [95% CI: 2.3–2.9] for 
501–1500 tests).
Discussion
We investigated the potential impact of PEPFAR-supported laboratory scale-up on the 
general (non-HIV) patient population in a country in sub-Saharan Africa. The results 
describe the number of laboratory tests performed in 2009 and 2011 in a convenience 
sample of PEPFAR-supported laboratories in Tanzania and the proportion of tests performed 
for patients referred from HIV services, NHSs and unknown sources. A key finding in this 
analysis is the substantial increase in the proportion of all tests referred from NHSs from 
2009 to 2011 – both when including all laboratory tests and when including only tests with 
known referral sources.
There was considerable variation in the number of tests performed by each facility (IQR: 
108–1211 tests in 2009 and 217–2034 in 2011). Also of note was the substantial variation in 
testing volume across different types of laboratory tests. Haematologic tests were the most 
common type and are the laboratory cornerstone for antenatal care, malaria diagnosis and 
treatment, routine outpatient diagnostics for infectious diseases, and HIV care. Syphilis tests 
were the least common test; however, the volume of syphilis tests increased substantially 
from 2009 to 2011, reflecting in part a Tanzania Ministry of Health recommendation for 
rapid tests kits (SD Bioline), which enabled routine point-of-care syphilis screening to 
become more feasible, as opposed to rapid plasma reagin, which require cold-chain analysis 
and trained laboratory staff.
Chemistry tests were performed most often for patients referred from HIV services, which 
may reflect the clinical practice of assessing renal function amongst HIV patients before and 
McNairy et al. Page 6













during antiretroviral therapy.11 It is difficult to interpret changes in tuberculosis testing 
given that the majority of laboratory registers did not record a referral source in this 
category.
Referral sources were not reported for any tests by 46% (43/94) of laboratories in 2009 and 
40% (40/101) of laboratories in 2011. It was not possible to infer the HIV status of these 
patients. In laboratories with unknown referrals amongst some tests, the intermittent lack of 
referral documentation may be due to random missing data at the laboratory. Alternatively, 
in some laboratories, technicians may prioritise documentation of samples from HIV clinics 
and leave all other referral sources blank, leading to samples referred from NHSs and those 
without a referral source being grouped together. In this scenario, patients with unknown 
referral sources would be more likely to represent the general population. If unknown 
referral sources were actually non-HIV patients, our data suggest little meaningful change in 
the proportion of tests referred from NHSs between 2009 and 2011, relative to tests referred 
by HIV services.
Limiting the analysis to laboratories that did record a referral source restricted the sample 
size to 51 in 2009 and 61 laboratories in 2011. Within this subgroup, the proportion of tests 
referred from NHSs increased across all test types, similar to analyses including the full 
sample of laboratories. A model was used to predict the odds that an individual test was 
referred from a NHS, given that individual tests are not independent of each other in a 
laboratory. Using this model, the probability of a test being referred from a NHS was two 
times higher in 2011 than in 2009. Notably, haematology and tuberculosis tests were less 
likely to be referred from a NHS in 2011 than in 2009. This finding may be due to the model 
taking into account the correlation of the laboratory tests within a specific site when 
estimating the odds ratios. For example, larger laboratories may have skewed the results 
reported in Figures 2 and 3, but once intrafacility correlation is accounted for, the proportion 
of tests referred from NHSs for haematology and tuberculosis appeared to decrease over 
time. These findings suggest a large amount of site-level variation in the odds of a test being 
referred from NHSs. In addition, the observed odds ratio for all tests was likely driven by 
the increases in NHS testing in chemistry and syphilis between 2009 and 2011.
Limitations
This study has several limitations. Firstly, the data comprised a non-random convenience 
sample of laboratories. Thus, the results may not be generalisable to other PEPFAR-
supported laboratories in Tanzania or in other PEPFAR-supported countries. It is also 
unknown, in the absence of a comparison group, whether the volume of laboratory tests 
referred from HIV services and NHSs would have changed in the absence of PEPFAR or at 
comparable public laboratories not supported by PEPFAR. Secondly, it would have been 
advantageous to describe the change in laboratory tests over a longer period. However, this 
was not feasible, as ICAP support for most study laboratories began in 2009. Thirdly, 
because the sources of the laboratory data did not record identifiable patient information, the 
unit of analysis in this study was a laboratory test and not an individual patient, who could 
have had multiple tests. As stated previously, the HIV status of the patient for whom each 
test was performed was unknown. Future analyses evaluating utilisation of laboratory 
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services at the patient level would provide additional information as to whether there are 
differences in laboratory usage according to patients’ HIV status. Fourthly, our data did not 
include information on the reason for a test being ordered for samples referred from NHSs. 
Thus, we could draw no conclusions as to whether or how guidelines for laboratory testing 
amongst non-HIV patients influenced utilisation of laboratory services. Finally, we were 
limited by the availability of hard-copy laboratory registers. The absence of a register did 
not necessarily mean that tests were not performed in a given laboratory, but merely that we 
were unable to access documentation of the test being performed. Even when registers were 
available, only 54% (51/94) of laboratories in 2009 and 61% (61/101) of laboratories in 
2011 recorded referral sources; amongst those that did, we could not verify the referral 
source against other records. However, data availability and quality are unlikely to have 
changed notably over the study period.
This study provides descriptive data as a departure point for answering the question of how 
PEPFAR's investment in laboratory services may have influenced utilisation of laboratory 
services by the general population. A systematic impact evaluation would be beneficial and 
would require prospective data or comparison groups and should include data on other 
variables about serviced populations, including the HIV status of patients for whom 
laboratory tests are performed, and laboratory characteristics, including staffing, equipment, 
training, quality improvement and costs.
Conclusion
This retrospective study found that in a convenience sample of PEPFAR-supported 
laboratories in Tanzania, the number and proportion of tests performed for patients referred 
from NHSs increased for all tests from 2009 to 2011 compared with referrals from HIV 
services. The increase was driven in part by chemistry and syphilis testing. Although these 
findings are descriptive and may not be generalisable to other HIV-supported laboratories in 
Tanzania and other resource-limited countries, this finding may reflect increased 
documentation of referrals from NHSs in laboratory registers over time. Another possibility 
is that laboratory scale-up originally intended to service the HIV-positive population in 
Tanzania may be associated with a ‘spillover effect’ on laboratory use amongst the general 
population in the sampled facilities. These data may inform subsequent prospective studies 
to evaluate the impact of PEPFAR-supported laboratory scale-up on utilisation of laboratory 
services and the impact on health outcomes amongst the general population
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Location of laboratories in Tanzania receiving PEPFAR support from ICAP during 2009 
and 2011 (N = 94 laboratories in 2009 and 101 in 2011).
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Referral sources for laboratory tests performed by PEPFAR-supported laboratories in 
Tanzania, 2009 and 2011. The graph depicts the overall proportion of laboratory tests 
performed for patents from different types of referral source (94 laboratories in 2009; 101 
laboratories in 2011).
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Proportion of tests referred from non-HIV services in 2009 and 2011 from amongst tests 
with a documented referral source. After excluding tests without a documented referral 
source, a total of 51 laboratories in 2009 and 61 laboratories in 2011 remained for the 
analysis. The total number of tests for which any referral status was available is shown for 
each year below the graph for each test category.
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Table 1
Characteristics of PEPFAR-supported laboratories in Tanzania for which data were provided for 2009 and 
2011.
Laboratory characteristics 2009 2011
N % N %
All laboratories 94 100 101 100
Location type
Urban 49 52 51 50
Rural 34 36 37 37
Missing data 11 12 13 13
Type of facility
Primary 59 63 66 65
Secondary 34 36 34 34
Tertiary 1 1 1.0 1
Region
Kagera 41 44 45 45
Kigoma 28 30 30 30
Pwani 18 19 19 19
Zanzibar 7 7 7 7
Median number of years of HIV care services
Median (IQR) 1 (1, 2) 3 (2, 4)
≤ 1 year 66 70 2 2
2–3 years 16 17 68 67
≥ 4 years 12 13 31 31
Number of HIV-positive patients enrolled in care†
Median (IQR) 139 (34, 558) 269 (82, 947)
< 100 34 36 25 25
100–499 25 27 31 31
≥ 500 22 23 32 32
Unknown 13 14 13 13
Number of laboratory technicians
Median (IQR) n/a 2 (1,4)
1 n/a 40 40
2–3 n/a 32 32
≥ 4 n/a 29 29
Test type
Haematology 60 64 93 92
Chemistry 12 13 23 23
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Laboratory characteristics 2009 2011
N % N %
Tuberculosis microscopy 80 85 89 88
Syphilis 30 32 46 46
Total number of tests conducted per laboratory
Median (IQR) 415 (108, 1211) 652 (217, 2034)
≤ 500 51 54 37 37
501–1500 25 27 36 36
> 1500 18 19 28 28
†
Data collected from a sample of the 127 PEPFAR-supported laboratories in Tanzania. IQR, interquartile range.
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